Table 1.

Correlation between AMC and CD68+ TAM and clinicopathological characteristics

	No. of patients	%	AMC			CD68+ TAM
			Low	High	p	Low	High	p
Age (years)					0.472			0.170
≤60	124	56.36	65	59		109	15
>60	96	43.64	55	41		78	18
Gender					0.554			0.558
Male	117	53.18	66	51		101	16
Female	103	46.82	54	49		86	17
KPS					0.322			0.833
<80	61	27.73	30	31		51	10
≥80	159	72.27	90	69		136	23
Tumor location					0.745			0.061
Upper	26	11.82	15	11		22	4
Middle	88	40.00	50	38		69	19
Lower	106	48.18	55	51		96	10
Tumor differentiation					0.001			0.886
Well	88	40.00	52	36		76	12
Moderate	84	38.18	53	31		71	13
Poor	48	21.82	15	33		40	8
Tumor length					0.019			0.022
≤4 cm	133	60.45	81	52		119	14
>4 cm	87	39.54	39	48		68	19
Perineural invasion					1.000			0.222
No	214	97.27	117	97		183	31
Yes	6	2.73	3	3		4	2
Vascular invasion					0.250			0.011
No	213	96.82	118	95		184	29
Yes	7	3.18	2	5		3	4
Treatment					0.550			0.304
Surgery only	102	46.36	51	51		91	11
Adjuvant chemotherapy	46	20.91	25	21		39	7
Adjuvant radiation	39	17.73	24	15		31	8
Adjuvant chemoradiation	33	15.00	20	13		26	7
Recurrence					1.000			0.466
No	38	17.27	21	17		34	4
Yes	182	82.73	99	83		153	29

Values in bold signify p < 0.05

AMC absolute monocyte count, TAM tumor-associated macrophages